^
Association details:
| Biomarker: | CHEK2 mutation |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
740P - Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC): Exploratory biomarker analyses of the phase IIIb OPINION study
Published date:
09/13/2021
Excerpt:
279 pts were enrolled and received olaparib maintenance (tablets; 300 mg bid)....12% of pts (34/279) had a non-BRCA HRRm (8 RAD51C; 7 BRIP1; 7 RAD51D; 3 CDK12; 2 FANCL; 2 PALB2; 1 ATM; 1 BARD1; 1 RAD51B; 1 CHEK2 and RAD51D; 1 PPP2R2A and RAD51C).....Pts with a non-BRCA HRRm achieved longer PFS benefit compared with the non HRRm subgroup.
Trial ID:
Source:
Title:
To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer
Excerpt:
...Documented germline or somatic mutation in BRCA1 or BRCA2 genes that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function) [Genetic counselling for patients with germline BRCA mutations should be performed according to local regulations] Or Tumour BRCAwt status and documented qualifying mutation in any of 13 genes involved in the HRR pathway, excluding BRCA1 and BRCA2 (ATM, BARD1, BRIP1,CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D,and RAD54L), identified by the Lynparza HRR Assay in archival tumour tissue (i.e.,BRCA-independent HRRm) 4....
Trial ID:
